Page last updated: 2024-10-17

aminocaproic acid and Renal Insufficiency

aminocaproic acid has been researched along with Renal Insufficiency in 6 studies

Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.
6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.

Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.

Research Excerpts

ExcerptRelevanceReference
" However, these studies have been criticized for including multiple centers and different dosing strategies."1.35Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. ( Lee, PH; Murphy, SA; Olenchock, SA; Symes, J; Tolis, G; Yehoshua, T, 2008)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19901 (16.67)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Makhija, N1
Sarupria, A1
Kumar Choudhary, S1
Das, S1
Lakshmy, R1
Kiran, U1
Weyand, AC1
Lombel, RM1
Pipe, SW1
Shavit, JA1
Olenchock, SA1
Lee, PH1
Yehoshua, T1
Murphy, SA1
Symes, J1
Tolis, G1
Hutton, B1
Joseph, L1
Fergusson, D1
Mazer, CD2
Shapiro, S1
Tinmouth, A1
LAGRUE, G1
MILLIEZ, P1
Body, SC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial[NCT03364491]Phase 311,000 participants (Actual)Interventional2018-03-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Hemoglobin

[Key secondary outcome] Change in hemoglobin from the most recent measured before delivery to lowest measured in the 48 hours after delivery (NCT03364491)
Timeframe: from 4 weeks before delivery to 48 hours postpartum

Interventiongrams per deciliter (Mean)
Tranexamic Acid-1.8
Placebo-1.9

Length of Stay

Mother's length of stay from delivery to discharge (NCT03364491)
Timeframe: Until hospital discharge, an average of 3 days

Interventiondays (Median)
Tranexamic Acid3
Placebo3

Number of Mothers Who Died or Had Thromboembolic Events (Venous or Arterial), Ischemic Stroke, Myocardial Infarction, New-onset Seizure Activity, or Were Admitted to the Intensive Care Unit for More Than 24 Hours

(NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid35
Placebo32

Number of Participants Who Received Open Label TXA or Other Antifibrinolytic

This is the number of mothers who were treated with any amount of open-label TXA (not blinded study drug) or another antifibrinolytic (eg., Amicar) (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid108
Placebo109

Number of Participants Who Received Surgical or Radiologic Interventions to Control Bleeding and Related Complications

This is the number of mothers who required any of the following types of surgical procedures to control bleeding: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid233
Placebo231

Number of Participants Who Received Treatments and Interventions in Response to Bleeding and Related Complications

[Key secondary outcome] This is the number of mothers who received treatments and interventions to control bleeding such as: uterotonics such as prostaglandins or methergine, but excluding oxytocin; open label TXA or other antifibrinolytics; transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates; laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid892
Placebo986

Number of Participants Who Were Transfused With 4 or More Units of Packed Red Blood Cells

Participants were categorized according to the amount of packed red blood cells or whole blood transfused, either as 0 to 3 units, or 4 or more units (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid20
Placebo19

Number of Participants Who Were Transfused With Other Blood Products

This is the number of mothers who received during the first 7 days after delivery a transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets, or received any factor concentrates (NCT03364491)
Timeframe: within 7 days postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid29
Placebo31

Number of Participants Who Were Treated With Uterotonics Other Than Oxytocin

This is the number of mothers who were treated with uterotonics such as prostaglandins or methergine, but excluding oxytocin, from delivery through 48 hours after delivery. (NCT03364491)
Timeframe: within 48 hours postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid649
Placebo732

Number of Participants With a Thromboembolic Event (Venous or Arterial), Ischemic Stroke, or Myocardial Infarction

[Key secondary outcome] This is the number of mothers who experienced a thromboembolic event, ischemic stroke, or myocardial infarction during the 6 weeks after delivery. (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid12
Placebo13

Number of Participants With Estimated Blood Loss Greater Than 1 Liter During Delivery

[Major secondary outcome] The surgeon or anesthesiologist estimated the blood loss during the delivery in milliliters, which was recorded in the anesthesia record and/or operative report (NCT03364491)
Timeframe: From skin incision to transfer from operating room, average of 1 hour

InterventionParticipants (Count of Participants)
Tranexamic Acid339
Placebo368

Number of Participants With Maternal Death or Transfusion of Packed Red Blood Cells

Participants were monitored from delivery until hospital discharge or 7 days after delivery (postpartum), whichever is sooner. This is the number of mothers who died for any reason, or had a blood transfusion of 1 or more units (of packed red blood cells, including whole blood or cell saver). (NCT03364491)
Timeframe: by hospital discharge or by 7 days postpartum, whichever is sooner

InterventionParticipants (Count of Participants)
Tranexamic Acid201
Placebo233

Number of Participants With Postpartum Infectious Complications

[Key Secondary Outcome] This is the number of mothers who experienced any of the following infectious complications in the 6 weeks after delivery: endometritis, surgical site infection, pelvic abscess (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid162
Placebo125

Number of Participants With Seizure Activity That Was Not Seen Prior to Study Enrollment

This is the number of mothers who experienced seizure activity, confirmed by central review, whose onset is after enrollment (NCT03364491)
Timeframe: within 6 weeks postpartum

InterventionParticipants (Count of Participants)
Tranexamic Acid2
Placebo0

Reviews

2 reviews available for aminocaproic acid and Renal Insufficiency

ArticleYear
Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies.
    BMJ (Clinical research ed.), 2012, Sep-11, Volume: 345

    Topics: Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Proced

2012
[NEPHROLOGY IN 1964].
    La Revue du praticien, 1964, Jun-21, Volume: 14

    Topics: Acute Kidney Injury; Aminocaproates; Aminocaproic Acid; Antineoplastic Agents; Diabetes Mellitus; Di

1964

Trials

1 trial available for aminocaproic acid and Renal Insufficiency

ArticleYear
Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
    Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:6

    Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aorta, Thoracic; Blood Loss, Surgical; Blood Tran

2013

Other Studies

3 other studies available for aminocaproic acid and Renal Insufficiency

ArticleYear
The Role of Platelets and ε-Aminocaproic Acid in Arthrogryposis, Renal Dysfunction, and Cholestasis (ARC) Syndrome Associated Hemorrhage.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:3

    Topics: Aminocaproic Acid; Arthrogryposis; Blood Platelets; Cholestasis; Female; Hemorrhage; Heterozygote; H

2016
Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients.
    The Annals of thoracic surgery, 2008, Volume: 86, Issue:2

    Topics: Aged; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Coronary Artery Bypass; Female; Humans;

2008
Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery.
    Anesthesia and analgesia, 2006, Volume: 103, Issue:6

    Topics: Aminocaproic Acid; Animals; Aprotinin; Blood Loss, Surgical; Cardiac Surgical Procedures; Drug Hyper

2006